Skip to main content
Q32 Bio Inc. logo

Q32 Bio Inc. — Investor Relations & Filings

Ticker · QTTB ISIN · US7469641051 LEI · 549300RWKPJEFTM3K452 US Professional, scientific and technical activities
Open in API
Filings indexed 507 across all filing types
Latest filing 2026-05-27 Capital/Financing Update
Country US United States of America
Listing US QTTB

About Q32 Bio Inc.

https://www.q32bio.com/

Q32 Bio Inc. is a clinical-stage biotechnology company developing therapies to restore healthy immune balance in patients with autoimmune and inflammatory diseases. The company's therapeutic approach targets powerful regulators of both the innate and adaptive immune systems. Its most advanced product candidate, bempikibart (ADX-914), is a fully human anti-interleukin-7 receptor alpha (IL-7Rα) antagonist monoclonal antibody. Bempikibart is designed to re-regulate adaptive immune function by blocking signaling from both interleukin-7 (IL-7) and thymic stromal lymphopoietin (TSLP). The candidate is currently being evaluated in a Phase 2 program for the treatment of alopecia areata.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 85% confidence The document is a Form 8-K current report under the Securities Exchange Act of 1934. Item 1.01 describes entry into a Securities Purchase Agreement with PIPE investors and the unregistered sale of equity securities, representing a financing transaction (sale of shares and pre-funded warrants) to raise capital. This is an update on the company’s fundraising/capital structure change, fitting the Capital/Financing Update category (CAP).
2026-05-27 English
10-Q - Q32 Bio Inc. (0001661998) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-05 English
8-K - Q32 Bio Inc. (0001661998) (Filer)
Earnings Release Classification · 85% confidence The document is a U.S. SEC Form 8-K “Current Report” filed May 5, 2026, under Item 2.02 “Results of Operations and Financial Condition,” and it furnishes a press release announcing the quarter ended March 31, 2026 financial results. This matches the definition of an Earnings Release (initial announcement of quarterly/periodical financial results). Q1 2026
2026-05-05 English
ARS - Q32 Bio Inc. (0001661998) (Filer)
Annual Report
2026-04-30 English
DEF 14A - Q32 Bio Inc. (0001661998) (Filer)
Proxy Solicitation & Information Statement
2026-04-30 English
424B5 - Q32 Bio Inc. (0001661998) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act, related to a controlled equity offering of common stock. It includes detailed information about the offering terms, risk factors, use of proceeds, plan of distribution, and legal matters. The document is clearly a registration and offering document for capital raising purposes, not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual offering document. Therefore, it fits the category of Capital/Financing Update (CAP).
2026-04-24 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.